Arcus Biosciences, Inc.
RCUS
$22.43
$0.220.99%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.92% | -83.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.92% | -83.75% | |||
| Cost of Revenue | -14.18% | 1.44% | |||
| Gross Profit | 23.48% | -647.62% | |||
| SG&A Expenses | -3.70% | -6.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.50% | 0.00% | |||
| Operating Income | 19.72% | -1,675.00% | |||
| Income Before Tax | 21.48% | -- | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.48% | -- | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.48% | -- | |||
| EBIT | 19.72% | -1,675.00% | |||
| EBITDA | 20.71% | -2,233.33% | |||
| EPS Basic | 29.43% | -11.37% | |||
| Normalized Basic EPS | 29.43% | -- | |||
| EPS Diluted | 29.43% | -11.37% | |||
| Normalized Diluted EPS | 29.43% | -- | |||
| Average Basic Shares Outstanding | 11.27% | 0.38% | |||
| Average Diluted Shares Outstanding | 11.27% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||